Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 14/07/2025

2,270 CHF (-3,20%)

(-3,20%) 14/07/2025

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d -3,20%
1 week1w -0,87%
1 maand1m 4,85%
3 maanden3m 114,96%
6 maanden6m 206,34%
1 jaar1j -1,13%
5 jaar5j -91,34%

woensdag 30 juli 2025, 07:00

Kwartaalcijfers (2de kwartaal)

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

30 juni 2025 · A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans · Persbericht

25 juni 2025 · Bondholders approve amended terms of the 2025 and 2028 convertible bonds · Persbericht

25 juni 2025 · Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds · Persbericht

23 juni 2025 · Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement · Persbericht

10 juni 2025 · Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia · Persbericht

6 juni 2025 · Idorsia publishes invitations to bondholder meetings · Persbericht

28 mei 2025 · Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025 · Persbericht

21 mei 2025 · New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability · Persbericht

2 mei 2025 · Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders · Persbericht

30 april 2025 · Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset · Persbericht

Profiel Idorsia Ltd

CEO: Jean-Paul Clozel

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe